Study measuring the cost associated with comorbidities in people living with HIV during the 2024–2034 period, based on national prevalence data and different assumptions regarding ART (antiretroviral therapy) regimens.
Study measuring the cost associated with comorbidities in people living with HIV during the 2024–2034 period, based on national prevalence data and different assumptions regarding ART (antiretroviral therapy) regimens.